Zobrazeno 1 - 10
of 57
pro vyhledávání: '"David L. Crandall"'
Autor:
Catherine A. Makarewich, Steven R. Houser, David L. Crandall, Walter J. Koch, Polina Gross, Constantine D Troupes, Sarah M. Schumacher
Publikováno v:
Journal of Molecular and Cellular Cardiology. 86:179-186
Rationale There is a current need for the development of new therapies for patients with heart failure. Objective We test the effects of members of the corticotropin-releasing factor (CRF) family of peptides on myocyte contractility to validate them
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab777e0d6abee8a11262649d94f79ae8
https://doi.org/10.1016/j.yjmcc.2015.07.023
https://doi.org/10.1016/j.yjmcc.2015.07.023
Autor:
David L. Crandall, C. Mugford, George P. Vlasuk, G. A. Morgan, R. E. Swillo, T. M. Antrilli, James K. Hennan, S. J. Gardell
Publikováno v:
Journal of Thrombosis and Haemostasis. 6:1558-1564
Summary. Objective: To assess the antithrombotic and profibrinolytic effects of tiplaxtinin (PAI-039), an orally bioavailable antagonist of PAI-1, in rat models of thrombosis. Methods and results: Carotid artery and vena cava vascular injury was prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3256aede7ae140fd5c328aa0114e28a2
https://doi.org/10.1111/j.1538-7836.2008.03063.x
https://doi.org/10.1111/j.1538-7836.2008.03063.x
Autor:
Robert G. Schaub, Valerie Clerin, David L. Crandall, Gray D. Shaw, Thomas M. Antrilli, Natalia Sushkova, Laura L. Carter, Christine Resmini, Patricia W. Bedard, Kristin Janz, James K. Hennan, Silvano DeBernardo, James C. Keith, Neelu Kaila, Qin Wang, Boris Tchernychev
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 324:497-506
P-selectin plays a significant and well documented role in vascular disease by mediating leukocyte and platelet rolling and adhesion. This study characterizes the in vitro activity, pharmacokinetic properties, and the anti-inflammatory and antithromb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3f0969afcb1b3977097a3ac40ce1a3
https://doi.org/10.1124/jpet.107.128124
https://doi.org/10.1124/jpet.107.128124
Autor:
George P. Vlasuk, Hassan Mahmoud Elokdah, Steven J. Orcutt, Stephen J. Gardell, Thomas A. Antrilli, Julie A. Krueger, David L. Crandall, Scott Mayer
Publikováno v:
Molecular Pharmacology. 72:897-906
PAI-749 is a potent and selective synthetic antagonist of plasminogen activator inhibitor 1 (PAI-1) that preserved tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) activities in the presence of PAI-1 (IC 50 value
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb47a7b62a5cd334bfcdcbf96be7b146
https://doi.org/10.1124/mol.107.037010
https://doi.org/10.1124/mol.107.037010
Autor:
David L. Crandall, Q.-Y. Liu, C. E. Leik, James K. Hennan, M. D. Basso, P. Nambi, N. L. Carson
Publikováno v:
British Journal of Pharmacology. 151:450-456
Background and purpose: Liver X receptors (LXRs) activate genes that regulate lipid and cholesterol metabolism. LXR agonists were shown recently to also increase murine renin gene expression in vivo. To further examine a link between lipid metabolism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8326ed556540cc0925e6bf3ee0119346
https://doi.org/10.1038/sj.bjp.0707241
https://doi.org/10.1038/sj.bjp.0707241
Autor:
David L Crandall
Publikováno v:
Future Lipidology. 2:5-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a5e9442dd4f7143af3d8d291d688bee
https://doi.org/10.2217/17460875.2.1.5
https://doi.org/10.2217/17460875.2.1.5
Autor:
Marie-Christine Alessi, Courtney E. Leik, Dawn A. Savio, David L. Crandall, Irène Juhan-Vague, Elaine M. Quinet, Amy L. Hreha, Soulaf El Ayachi
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 26:2209-2215
Objective— The effect of a novel small molecule plasminogen activator inhibitor (PAI-1) inhibitor on adipose tissue physiology was investigated. Methods and Results— In human preadipocyte cultures, PAI-039 inhibited both basal and glucose-stimula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0ba45eb6614fe9d8af51266259c37b
https://doi.org/10.1161/01.atv.0000235605.51400.9d
https://doi.org/10.1161/01.atv.0000235605.51400.9d
Autor:
Thomas M. Antrilli, Gwen A. Morgan, Robert E. Swillo, Girija Krishnamurthy, James K. Hennan, David L. Crandall, Hassan Mahmoud Elokdah, Jean S Bauer
Publikováno v:
Biochemical and Biophysical Research Communications. 311:904-908
Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of tissue plasminogen activator (tPA) and is elevated in diseases of vascular remodeling. In this study, we describe an inhibitor of active PAI-1, WAY-140312. Using fluore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a006371b9a510cd5e44b1131e51743ca
https://doi.org/10.1016/j.bbrc.2003.10.088
https://doi.org/10.1016/j.bbrc.2003.10.088
Publikováno v:
Journal of Biological Chemistry. 278:16329-16335
The mechanism for the conversion of plasminogen activator inhibitor-1 (PAI-1) from the active to the latent conformation is not well understood. Recently, a monoclonal antibody, 33B8, was described that rapidly converts PAI-1 to the latent conformati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bde5647e967bafdaa1e652f329fed7f4
https://doi.org/10.1074/jbc.m208420200
https://doi.org/10.1074/jbc.m208420200